Third Harmonic Bio Inc.

NASDAQ THRD

Download Data

Third Harmonic Bio Inc. Revenue Per Share 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Third Harmonic Bio Inc. Revenue Per Share 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Third Harmonic Bio Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 0.00, a 0.00% change year over year.
  • Third Harmonic Bio Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 0.00.
NASDAQ: THRD

Third Harmonic Bio Inc.

CEO Ms. Natalie C. Holles
IPO Date Sept. 14, 2022
Location United States
Headquarters 300 Technology Square, Cambridge, MA, United States, 02139
Employees 31
Sector Healthcare
Industry Biotechnology
Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Similar companies

NXTC

NextCure  Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

RLYB

Rallybio Corp

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email